Capital Directions Investment Advisors LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 6,047 shares of the company’s stock after selling 545 shares during the period. Johnson & Johnson makes up about 0.3% of Capital Directions Investment Advisors LLC’s investment portfolio, making the stock its 28th biggest position. Capital Directions Investment Advisors LLC’s holdings in Johnson & Johnson were worth $996,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the company. Solstein Capital LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $30,000. Newton One Investments LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $31,000. Robbins Farley LLC acquired a new position in Johnson & Johnson in the second quarter worth $33,000. Alpha Paradigm Partners LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $47,000. Finally, Annapolis Financial Services LLC boosted its position in Johnson & Johnson by 109.4% during the 2nd quarter. Annapolis Financial Services LLC now owns 312 shares of the company’s stock valued at $51,000 after purchasing an additional 163 shares during the period. Institutional investors own 67.29% of the company’s stock.
JNJ has been the subject of several analyst reports. SVB Leerink reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Wells Fargo & Company reiterated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, October 7th. Finally, Morgan Stanley cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price target on the stock. in a research report on Tuesday, September 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $190.38.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.19. Johnson & Johnson had a return on equity of 37.06% and a net margin of 19.92%. The company had revenue of $23.31 billion during the quarter, compared to analyst estimates of $22.54 billion. During the same quarter in the prior year, the company earned $1.67 earnings per share. The company’s revenue for the quarter was up 27.1% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 9.65 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Tuesday, August 24th were paid a dividend of $1.06 per share. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 annualized dividend and a yield of 2.63%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 52.80%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Further Reading: Dual Listing What You Need to Know
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.